Literature DB >> 25549804

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.

Massimo Breccia1, Matteo Molica, Gioia Colafigli, Irene Zacheo, Roberto Latagliata, Agostino Tafuri, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25549804     DOI： 10.3109/10428194.2014.993391

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

Review 1.  The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Authors:  Guray Saydam; Ridvan Ali; Ahmet Muzaffer Demir; Ahmet Emre Eskazan; Birol Guvenc; Ibrahim Celalettin Haznedaroglu; Mehmet Ali Ozcan; Ozan Salim; Mehmet Sonmez; Ayse Tulin Tuglular; Mehmet Turgut; Ali Unal; Birkan Aver; Sirac Bozkurt; Begum Ozdengulsun; Osman Ilhan
Journal:  Int J Hematol Oncol       Date:  2022-05-24

2.  Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq.

Authors:  Rafid A Abood; Hasson M Hasson; Asaad A Khalaf; Elaf M Saleh
Journal:  Sultan Qaboos Univ Med J       Date:  2019-11-05

3.  The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.

Authors:  Mohammad Mohammadi; Yang Cao; Ingrid Glimelius; Matteo Bottai; Sandra Eloranta; Karin E Smedby
Journal:  BMC Cancer       Date:  2015-11-05       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.